Bill > S2062

This bill, known as the RAPID Reserve Act (Rolling Active Pharmaceutical Ingredient and Drug Reserve Act), aims to improve the resilience of critical drug supply chains in the United States by establishing a new program managed by the Secretary of Health and Human Services. The bill requires eligible entities (such as drug manufacturers, pharmaceutical ingredient producers, and distributors) to maintain a 6-month reserve of critical drugs and their active pharmaceutical ingredients that have vulnerable supply chains. These entities would be required to keep these reserves in domestic or OECD-country establishments, regularly replenish them, and be prepared to produce drugs at the Secretary's direction during emergencies. The bill gives preference to domestic manufacturers and seeks to strengthen U.S. manufacturing capacity by awarding contracts and cooperative agreements to entities committed to quality systems, domestic production, and surge capacity. Eligible drugs will be determined based on their potential importance during public health emergencies, their critical nature to the healthcare system, and supply chain vulnerabilities. The program is authorized with $500 million in funding for fiscal year 2026, and the Secretary must report to Congress every two years on the program's effectiveness and the list of eligible drugs. The ultimate goal is to prevent drug shortages and ensure the United States can respond effectively to potential health crises or threats.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/2062/all-info